- Home
- TVTX
as 06-18-2025 4:00pm EST
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.4B | IPO Year: | N/A |
| Target Price: | $33.57 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.80 - $25.29 | Next Earning Date: | 07-31-2025 |
| Revenue: | $273,533,000 | Revenue Growth: | 75.65% |
| Revenue Growth (this year): | 73.84% | Revenue Growth (next year): | 46.72% |
Stock Insider Trading Activity of Travere Therapeutics Inc. (TVTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dube Eric M | TVTX | CHIEF EXECUTIVE OFFICER | May 2 '25 | Sell | $21.05 | 18,924 | $398,350.20 | 419,173 | |
| ROTE WILLIAM E. | TVTX | Chief Research Officer | May 2 '25 | Sell | $21.05 | 3,198 | $67,317.90 | 100,241 | |
| REED ELIZABETH E | TVTX | Chief Legal Officer and GC | May 2 '25 | Sell | $21.05 | 4,920 | $103,566.00 | 89,482 | |
| Heerma Peter | TVTX | CHIEF COMMERCIAL OFFICER | May 2 '25 | Sell | $21.05 | 1,771 | $37,279.55 | 128,215 | |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | May 2 '25 | Sell | $21.05 | 1,784 | $37,553.20 | 93,126 | |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | Apr 11 '25 | Sell | $13.14 | 48 | $630.94 | 93,126 |
Latest Travere Therapeutics Inc. News
TVTX Breaking Stock News: Dive into TVTX Ticker-Specific Updates for Smart Investing
Insider Monkey
7 days ago
HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs
Business Wire
8 days ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
9 days ago
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference
Business Wire
10 days ago
Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day
Business Wire
17 days ago
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress
PR Newswire
a month ago
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
Business Wire
a month ago
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS
GlobeNewswire
a month ago
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
Compare TVTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TVTX Travere Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.